På basis af den kliniske fase 3 undersøgelse forventes næsten alle patienter at udvikle IgG- antistoffer over for laronidase, for det meste inden for 3 måneder efter behandlingens påbegyndelse.
Based on the Phase 3 clinical trial, almost all patients are expected to develop IgG antibodies to laronidase, mostly within 3 months of initiation of treatment.